{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:57:34Z","timestamp":1786636654552,"version":"build-2736575974"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Mid-life Health"],"published-print":{"date-parts":[[2012]]},"DOI":"10.4103\/0976-7800.98811","type":"journal-article","created":{"date-parts":[[2012,7,20]],"date-time":"2012-07-20T19:53:11Z","timestamp":1342813991000},"page":"10","source":"Crossref","is-referenced-by-count":17,"title":["Various treatment options for benign prostatic hyperplasia: A current update"],"prefix":"10.4103","volume":"3","author":[{"given":"Alankar","family":"Shrivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VipinB","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0976-7800.98811-1","first-page":"88","volume-title":"Induction of prostate apoptosis by \u03b11 -adrenoceptor antagonists: Mechanistic significance of the quinazoline component","author":"Anglin","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"key-10.4103\/0976-7800.98811-2","first-page":"7","volume-title":"Cancer statistics, 2000","author":"Greenlee","year":"2000","journal-title":"CA Cancer J Clin"},{"key":"key-10.4103\/0976-7800.98811-3","doi-asserted-by":"crossref","unstructured":"Boyle P. Prostate Cancer 2000; evolution of an epidemic of unknown origin. In: Dennis L, editor. Prostate Cancer 2000. Heidelberg: Springer; 1994. p. 5-11.","DOI":"10.1007\/978-3-642-79178-9_3"},{"key":"key-10.4103\/0976-7800.98811-4","first-page":"433","volume-title":"Role of androgens in prostatic cancer","author":"Isaacs","year":"1994","journal-title":"Vitam Horm"},{"key":"key-10.4103\/0976-7800.98811-5","first-page":"948","volume-title":"Detection of organ confined prostate cancer is associated through prostate-specific antigen-based screening","author":"Catalona","year":"1993","journal-title":"JAMA"},{"key":"key-10.4103\/0976-7800.98811-6","first-page":"365","volume-title":"Effect of patient age on early detection of prostate cancer with prostate specific antigen and digital rectal examination","author":"Richie","year":"1993","journal-title":"Urology"},{"key":"key-10.4103\/0976-7800.98811-7","first-page":"371","volume-title":"Non-hormone chemotherapy for prostate cancer: Principles of treatment and application to the testing of new drugs","author":"Raghavan","year":"1988","journal-title":"Semin Oncol"},{"key":"key-10.4103\/0976-7800.98811-8","doi-asserted-by":"crossref","unstructured":"Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. Affiliations department of medical physics, memorial sloan-kettering cancer center, 1275 York Ave., New York, NY 10021, USA. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24.","DOI":"10.1056\/NEJM198908173210702"},{"key":"key-10.4103\/0976-7800.98811-9","first-page":"755","volume-title":"Neoadjuvant hormonal therapy improves the therapeutic ration in patients with bulky prostatic disease treated with three dimensional conformal therapy","author":"Zelefsky","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key-10.4103\/0976-7800.98811-10","first-page":"797","volume-title":"Current models of human prostate contractility","author":"Haynes","year":"2005","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"key-10.4103\/0976-7800.98811-11","first-page":"1439","volume-title":"Comparison of effects of alpha receptor blockers on endothelial functions and coagulation parameters in patients with benign prostatic hyperplasia.Prostatic diseases and male voiding dysfunction","author":"Alan","year":"2011","journal-title":"Urology"},{"key":"key-10.4103\/0976-7800.98811-12","first-page":"1006","volume-title":"Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia","author":"Nordling","year":"2005","journal-title":"BJU Int"},{"key":"key-10.4103\/0976-7800.98811-13","first-page":"233","volume-title":"Epidemiology and natural history of benign prostatic hyperplasia","author":"Tsukamoto","year":"1997","journal-title":"Int J Urol"},{"key":"key-10.4103\/0976-7800.98811-14","first-page":"e1","volume-title":"JUA clinical guidelines for benign prostatic hyperplasia","author":"Homma","year":"2011","journal-title":"Int J Urol"},{"key":"key-10.4103\/0976-7800.98811-15","first-page":"757","volume-title":"Comparative efficacy of two a1-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement","author":"de","year":"2004","journal-title":"BJU Int"},{"key":"key-10.4103\/0976-7800.98811-16","first-page":"1227","volume-title":"The economics of benign prostatic hyperplasia: A literature review","author":"Kortt","year":"1996","journal-title":"Clin Ther"},{"key":"key-10.4103\/0976-7800.98811-17","first-page":"3","volume-title":"Current role of a-blockers in the treatment of benign prostatic hyperplasia","author":"Kaplan","year":"2008","journal-title":"BJU Int"},{"key":"key-10.4103\/0976-7800.98811-18","first-page":"863","volume-title":"The correlation between inflammation, BPH and prostate cancer","author":"Djavan","year":"2009","journal-title":"Eur Urol Suppl"},{"key":"key-10.4103\/0976-7800.98811-19","first-page":"3292","volume-title":"(Arylpiperazinyl) cyclohexylsufonamides: Discovery of \u03b11a \/ 1d -selective adrenergic receptor antagonists for the treatment of Benign Prostatic Hyperplasia\/Lower Urinary Tract Symptoms (BPH\/LUTS)","author":"Chiu","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"key-10.4103\/0976-7800.98811-20","first-page":"5","volume-title":"Drug treatment for LUTS and BPH: New is not always better","author":"Roehrborn","year":"2006","journal-title":"Eur Urol"},{"key":"key-10.4103\/0976-7800.98811-21","first-page":"360","volume-title":"First-line treatment for symptomatic benign prostatic hyperplasia: Is there a particular patient profile for a particular treatment?","author":"Gonzalez","year":"2006","journal-title":"World J Urol"},{"key":"key-10.4103\/0976-7800.98811-22","first-page":"989","volume-title":"Medical therapy for BPH: What factors should we consider?","author":"Rigatti","year":"2006","journal-title":"Eur Urol Suppl"},{"key":"key-10.4103\/0976-7800.98811-23","first-page":"418","volume-title":"Critical review of guidelines for BPH diagnosis and treatment strategy","author":"Novara","year":"2006","journal-title":"Eur Urol Suppl"},{"key":"key-10.4103\/0976-7800.98811-24","first-page":"613","volume-title":"The natural history of untreated \u2032prostatism\u2032","author":"Ball","year":"1981","journal-title":"Br J Urol"},{"key":"key-10.4103\/0976-7800.98811-25","first-page":"1097","volume-title":"Signal transduction and regulation: Are all a1-adrenergic receptor subtypes created equal?","author":"Hein","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"key-10.4103\/0976-7800.98811-26","first-page":"420","volume-title":"Are all alpha-blockers created the same?","author":"Irani","year":"2006","journal-title":"Eur Urol"},{"key":"key-10.4103\/0976-7800.98811-27","first-page":"1004","volume-title":"Safety and tolerability of treatment for BPH","author":"Montorsi","year":"2006","journal-title":"Eur Urol Suppl"},{"key":"key-10.4103\/0976-7800.98811-28","first-page":"342","volume-title":"Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: Results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe","author":"Chapple","year":"2011","journal-title":"Eur Urol"},{"key":"key-10.4103\/0976-7800.98811-29","first-page":"S25","volume-title":"Treatment of benign prostatic hyperplasia and aging: Impacts of alpha-1 blockers on sexual function","author":"Takahashi","year":"2011","journal-title":"J Mens Health"},{"key":"key-10.4103\/0976-7800.98811-30","doi-asserted-by":"crossref","unstructured":"Schilit S, Benzeroual KE. Silodosin: A selective \u03b11A -adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia. Clin Ther 2009;31:2489-502.","DOI":"10.1016\/j.clinthera.2009.11.024"},{"key":"key-10.4103\/0976-7800.98811-31","first-page":"19","volume-title":"Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: The cardiovascular system","author":"Barendrecht","year":"2005","journal-title":"BJU Int"},{"key":"key-10.4103\/0976-7800.98811-32","first-page":"113","volume-title":"Managing benign prostatic hyperplasia and prostate cancer - the challenges today","author":"Marberger","year":"2010","journal-title":"J Mens Health"},{"key":"key-10.4103\/0976-7800.98811-33","first-page":"109","volume-title":"An overview on 5 a -reductase inhibitors","author":"Aggarwal","year":"2010","journal-title":"Steroids"},{"key":"key-10.4103\/0976-7800.98811-34","first-page":"4920","volume-title":"Self organizing molecular field analysis on a series of human 5 a-reductase inhibitors: Unsaturated 3-carboxysteroid","author":"Thareja","year":"2009","journal-title":"Eur J Med Chem"},{"key":"key-10.4103\/0976-7800.98811-35","first-page":"32","volume-title":"Steroid 5 a-reductase inhibitors targeting BPH and prostate cancer","author":"Schmidt","year":"2011","journal-title":"J Steroid Biochem Mol Biol"},{"key":"key-10.4103\/0976-7800.98811-36","first-page":"481","volume-title":"4-(1-Benzoylindol-3-yl) butyric acids and FK-143: Novel nonsteroidal inhibitors of steroid 5 a -reductase (II)","author":"Sawada","year":"1999","journal-title":"Chem Pharm Bull"},{"key":"key-10.4103\/0976-7800.98811-37","first-page":"357","volume-title":"FK143, a novel, nonsteroidal inhibitor of steroid 5 a -reductase.(1) In vitro effects on human and animal prostatic enzymes","author":"Hirosumi","year":"1995","journal-title":"J Steroid Biochem Mol Biol"},{"key":"key-10.4103\/0976-7800.98811-38","doi-asserted-by":"crossref","unstructured":"Hirosumi J, Nakayama O, Chida N, Inami M, Fagan T, Sawada K, et al. FK143, a novel nonsteroidal inhibitor of steroid 5 a-reductase. 2. In vivo effects on rat and dog prostates. J Steroid Biochem Mol Biol 1995;52:365-73.","DOI":"10.1016\/0960-0760(94)00188-R"},{"key":"key-10.4103\/0976-7800.98811-39","first-page":"628","volume-title":"The MTOPS Study: New findings, new insights, and clinical implications for the management of BPH","author":"Marberger","year":"2006","journal-title":"Eur Urol Suppl"},{"key":"key-10.4103\/0976-7800.98811-40","first-page":"387","volume-title":"A review of combination Therapy in patients with benign prostatic hyperplasia","author":"McVary","year":"2007","journal-title":"Clin Ther"},{"key":"key-10.4103\/0976-7800.98811-41","first-page":"123","volume-title":"The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study","author":"Roehrborn","year":"2010","journal-title":"Eur Urol"},{"key":"key-10.4103\/0976-7800.98811-42","first-page":"533","volume-title":"The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia","author":"Lepor","year":"1996","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0976-7800.98811-43","first-page":"72","volume-title":"Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH)","author":"Di","year":"2005","journal-title":"Eur Urol"},{"key":"key-10.4103\/0976-7800.98811-44","first-page":"2319","volume-title":"Tolteradine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: A randomized control trial","author":"Kaplan","year":"2006","journal-title":"JAMA"},{"key":"key-10.4103\/0976-7800.98811-45","first-page":"7","volume-title":"Impact of treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in aging men","author":"Shiu-Dong","year":"2007","journal-title":"Incont Pelvic Floor Dysfunct"},{"key":"key-10.4103\/0976-7800.98811-46","first-page":"282","volume-title":"Benign prostatic hyperplasia","author":"McNicholas","year":"2011","journal-title":"Surgery (Oxford),"},{"key":"key-10.4103\/0976-7800.98811-47","first-page":"131","volume-title":"Heat versus drugs in the treatment of benign prostatic hyperplasia","author":"Djavan","year":"2003","journal-title":""},{"key":"key-10.4103\/0976-7800.98811-48","first-page":"389","volume-title":"Transurethral microwave thermotherapy for the treatment of BPH: Still a challenger?","author":"Herrmann","year":"2006","journal-title":"World J Urol"},{"key":"key-10.4103\/0976-7800.98811-49","first-page":"836","volume-title":"A systematic review of Cernilton for the treatment of benign prostatic hyperplasia","author":"MacDonald","year":"1999","journal-title":"BJU Int"},{"key":"key-10.4103\/0976-7800.98811-50","first-page":"21","volume-title":"Symptomatic comparison in efficacy on patients with benign prostatic hyperplasia treated with two therapeutic approaches","author":"Li","year":"2010","journal-title":"Complement Ther Med"},{"key":"key-10.4103\/0976-7800.98811-51","first-page":"203","volume-title":"Inhibitory effect of traditional Chinese medicine Zi-Shen Pill on benign prostatic hyperplasia in rats","author":"Sun","year":"2008","journal-title":"J Ethnopharmacol"},{"key":"key-10.4103\/0976-7800.98811-52","first-page":"135","volume-title":"Effects of a nanocomposite containing Orbignya speciosa lipophilic extract on Benign Prostatic Hyperplasia","author":"de","year":"2011","journal-title":"J Ethnopharmacol"},{"key":"key-10.4103\/0976-7800.98811-53","first-page":"196","volume-title":"Extracts of bark from the traditional Chinese herb Phellodendron amurense inhibit contractility of the isolated rat prostate gland","author":"Xu","year":"2010","journal-title":"J Ethnopharmacol"},{"key":"key-10.4103\/0976-7800.98811-54","first-page":"107","volume-title":"Anti-androgenic activities of Ganoderma lucidum","author":"Fujita","year":"2005","journal-title":"J Ethnopharmacol"},{"key":"key-10.4103\/0976-7800.98811-55","first-page":"269","volume-title":"Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), tamsulosin or finasteride","author":"Zlotta","year":"2005","journal-title":"Eur Urol"},{"key":"key-10.4103\/0976-7800.98811-56","first-page":"894","volume-title":"The role of serenoa repens in the clinical management of lower urinary tract symptoms due to benign prostatic hyperplasia","author":"Franklin","year":"2009","journal-title":"Eur Urol"},{"key":"key-10.4103\/0976-7800.98811-57","first-page":"139","volume-title":"Und der interdisziplin\u00e4 rer Arbeitskreis Prostata.Placebokontrollierte Langzeittherapiestudie mit K\u00fc rbissamenextrakt bei BPH-bedingten Miktionsbeschwerden","author":"Bach","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/0976-7800.98811-58","first-page":"460","volume-title":"Dose-response effect of Red Maca (Lepidium meyenii) on benign prostatic hyperplasia induced by testosterone enanthate","author":"Gasco","year":"2007","journal-title":"Phytomedicine"},{"key":"key-10.4103\/0976-7800.98811-59","unstructured":"Chirumamilla MM. Prostate gland enlargement and ayurvedic treatment. Available from: http:\/\/www.muralimanohar.com\/Articles,%20English\/Diseases%20and%20Conditions\/Prostate%20Gland%20Enlargement.htm. [Last cited on 2012 May 15]."},{"key":"key-10.4103\/0976-7800.98811-60","unstructured":"Ayurvedic treatment for enlarged prostate. Available from: http:\/\/ayurveda-foryou.com\/treat\/prostate1.html. [Last cited on 2012 May 15]."},{"key":"key-10.4103\/0976-7800.98811-61","unstructured":"Ayurvedic medicines Tablets 1. Available from: http:\/\/ayurveda-foryou.com\/paypalstore\/tablet1.html#chandraprabha. [Last cited on 2012 May 15]."},{"key":"key-10.4103\/0976-7800.98811-62","unstructured":"Planet Ayurveda. Effective prostate herbal remedies. Available from: http:\/\/www.planetayurveda.com\/prostate-herbal-remedies.htm. [Last cited on 2012 May 15]."},{"key":"key-10.4103\/0976-7800.98811-63","unstructured":"Express pharma. Available from: http:\/\/www.expresspharmaonline.com\/20080115\/management05.shtml. [Last updated in 2008 Jan 1-15, Last cited on 2012 May 15]."},{"key":"key-10.4103\/0976-7800.98811-64","unstructured":"Himalaya pharmaceuticals. Himplasia. Available from: http:\/\/www.himalayahealthcare.com\/products\/himplasia.htm. [Last cited on 2012 May 15]."},{"key":"key-10.4103\/0976-7800.98811-65","first-page":"311","volume-title":"Bangshil and Fortege in prostatic congestion","author":"Joseph","year":"1980","journal-title":"Curr Med Pract"},{"key":"key-10.4103\/0976-7800.98811-66","first-page":"549","volume-title":"Intake of selected micronutrients and the risk of surgically treated benign prostatic hyperplasia: A case-control study from Italy","author":"Tavani","year":"2006","journal-title":"Eur Urol"},{"key":"key-10.4103\/0976-7800.98811-67","first-page":"1271","volume-title":"The synthesis of N-phenoxyethyl-1-substituted-1,2,3,4-tetrahydroisoquinolines and their \u03b11 -adrenoceptor blocking activity","author":"Chen-Yuan","year":"2009","journal-title":"Eur J Med Chem"},{"key":"key-10.4103\/0976-7800.98811-68","first-page":"1003","volume-title":"An improved synthesis of enantiomerically pure RWJ 69442, a development candidate for the treatment of benign prostatic hyperplasia","author":"Kuo","year":"2001","journal-title":"J Heterocycl Chem"},{"key":"key-10.4103\/0976-7800.98811-69","first-page":"639","volume-title":"Botulinum toxin in the treatment of OAB, BPH, and IC","author":"Smith","year":"2009","journal-title":"Toxicon"},{"key":"key-10.4103\/0976-7800.98811-70","first-page":"670","volume-title":"Prostatic botulinum A toxin injection - an alternative treatment for benign prostatic obstruction in poor surgical candidates","author":"Kuo","year":"2005","journal-title":"Urology"},{"key":"key-10.4103\/0976-7800.98811-71","first-page":"3000","volume-title":"Discovery of LASSBio-772, a 1,3-benzodioxole N-phenylpiperazine derivative with potent alpha 1A\/D-Adrenergic receptor blocking properties","author":"Romeiro","year":"2011","journal-title":"Eur J Med Chem"},{"key":"key-10.4103\/0976-7800.98811-72","first-page":"875","volume-title":"Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure?","author":"Rohrer","year":"2011","journal-title":"J Card Fail"},{"key":"key-10.4103\/0976-7800.98811-73","first-page":"237","volume-title":"Role of interleukins, IGF and stem cells in BPH","author":"McLaren","year":"2011","journal-title":"Differentiation"},{"key":"key-10.4103\/0976-7800.98811-74","first-page":"436","volume-title":"Prostatic diseases and male voiding dysfunction: Reduction of prostate-specific antigen after tamsulosin treatment in patients with elevated prostate-specific antigen and lower urinary tract symptoms associated with low incidence of prostate cancer at biopsy","author":"Tubaro","year":"2010","journal-title":"Urology"}],"container-title":["Journal of Mid-life Health"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:59:35Z","timestamp":1786633175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0976-7800.98811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"alternative-id":["98811"],"URL":"https:\/\/doi.org\/10.4103\/0976-7800.98811","relation":{},"ISSN":["0976-7800"],"issn-type":[{"value":"0976-7800","type":"print"}],"subject":[],"published":{"date-parts":[[2012]]}}}